2023-09-11 11:45:10
The Russian Ministry of Health has approved the first vaccine for the prevention of herpes zoster, Shingrix. The drug has already been approved for use in the US and EU.
GSK has received a registration certificate in Russia for the recombinant, adjuvanted vaccine Shingrix for the prevention of herpes zoster. Information published in the State Register of Medicines, reports the Pharmaceutical Bulletin.
The vaccine contains glycoprotein E, a protein found in the chickenpox virus. The drug also includes an adjuvant system consisting of plant extract QS-21 and bacterial extract MPL to improve the body’s response to the vaccine.
Shingrix is indicated for the prevention of herpes zoster and related complications in adults 50 years of age and older, and in adults 18 years of age and older with an increased risk of developing herpes zoster. The vaccine is administered twice at an interval of two to six months.
The drug is available in the form of a lyophilisate for the preparation of a suspension for intramuscular administration. The kit contains a suspension containing an adjuvant intended for diluting the lyophilized vaccine.
The drug may cause undesirable reactions in the form of chills, fever, headache, allergic reactions, etc., as indicated in the instructions for medical use.
Herpes zoster (shingles) is a viral infection caused by the varicella zoster virus (human herpes virus type III). In people who have had chickenpox, the virus goes into a latent state in the nerve ganglia. Herpes zoster is characterized by the appearance of a painful rash on the body. Typically, herpes zoster affects people over 50 years of age and patients with weakened immune systems: HIV-infected people, cancer patients, taking corticosteroids and immunosuppressive drugs.
The Shingrix vaccine received approval from the US Food and Drug Administration (FDA) in 2017.
1694555260
#Ministry #Health #approved #vaccine #herpes #zoster #Medvestnik
